GlassScriptPhysician profile
Necia Jo Garrett
NPI 1710342456
$5,257.60
in general payments reported to CMS, 2019-2025
44 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $796 · 2023: $1,352 · 2024: $1,314 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.06 | 2021-2025 | |
| Novo Nordisk INC | $554.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $426.64 | 2021-2025 | |
| Lilly USA, LLC | $382.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $318.53 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $246.01 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $235.36 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $232.82 | 2023-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.73 | 2021-2025 | Jardiance, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $114.74 | 2021-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.97 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $96.65 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.02 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $89.02 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $88.92 | 2022-2024 | Austedo Xr |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $75.56 | 2023-2025 | Rexulti, Vyepti |
| E.R. Squibb & Sons, L.L.C. | $69.46 | 2021-2024 | Eliquis, Camzyos |
| Axsome Therapeutics, INC. | $64.49 | 2022-2024 | Auvelity |
| Exact Sciences Corporation | $63.23 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $53.59 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $50.81 | 2021-2024 | Veozah |
| Medtronic, INC. | $42.84 | 2021-2023 | Minimed 780g |
| Tris Pharma INC | $40.74 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $39.90 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $36.17 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $36.14 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $33.37 | 2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $29.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.27 | 2022-2023 | Quviviq |
| Ibsa Pharma INC. | $20.56 | 2025 | Flector, Licart, Tirosint |
| Vanda Pharmaceuticals INC. | $19.89 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $19.65 | 2025 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $19.19 | 2022 | |
| Ardelyx, INC. | $17.52 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $16.77 | 2021 | |
| Amarin Pharma, INC. | $16.67 | 2021 | |
| Sumitomo Pharma America, INC. | $15.87 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $15.81 | 2025 | Nexletol |
| Neurelis, INC. | $15.26 | 2023 | Valtoco |
| Eisai INC. | $14.40 | 2021 | |
| Impel Pharmaceuticals INC. | $13.76 | 2022 | |
| Mylan Specialty L.P. | $13.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.33 | 2021 | |
| Endogastric Solutions, INC | $7.10 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Necia Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.